PL1974017T3 - Środki i sposoby do wpływania na stabilność komórek wytwarzających przeciwciała - Google Patents

Środki i sposoby do wpływania na stabilność komórek wytwarzających przeciwciała

Info

Publication number
PL1974017T3
PL1974017T3 PL06824300T PL06824300T PL1974017T3 PL 1974017 T3 PL1974017 T3 PL 1974017T3 PL 06824300 T PL06824300 T PL 06824300T PL 06824300 T PL06824300 T PL 06824300T PL 1974017 T3 PL1974017 T3 PL 1974017T3
Authority
PL
Poland
Prior art keywords
influencing
stability
methods
producing cells
antibody producing
Prior art date
Application number
PL06824300T
Other languages
English (en)
Other versions
PL1974017T5 (pl
Inventor
Hergen Spits
Ferenc Alexander Scheeren
Tim Beaumont
Sean Andrew Diehl
Original Assignee
Academisch Medisch Centrum Bij De Univ Van Amsterdam
Aimm Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37714656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1974017(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/NL2005/000848 external-priority patent/WO2007067032A1/en
Application filed by Academisch Medisch Centrum Bij De Univ Van Amsterdam, Aimm Therapeutics Bv filed Critical Academisch Medisch Centrum Bij De Univ Van Amsterdam
Publication of PL1974017T3 publication Critical patent/PL1974017T3/pl
Publication of PL1974017T5 publication Critical patent/PL1974017T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
PL06824300.5T 2005-12-09 2006-12-08 Środki i sposoby do wpływania na stabilność komórek wytwarzających przeciwciała PL1974017T5 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/NL2005/000848 WO2007067032A1 (en) 2005-12-09 2005-12-09 Means and methods for influencing the stability of cells
EP06076211 2006-06-12
PCT/NL2006/000625 WO2007067046A1 (en) 2005-12-09 2006-12-08 Means and methods for influencing the stability of antibody producing cells
EP06824300.5A EP1974017B2 (en) 2005-12-09 2006-12-08 Means and methods for influencing the stability of antibody producing cells

Publications (2)

Publication Number Publication Date
PL1974017T3 true PL1974017T3 (pl) 2014-04-30
PL1974017T5 PL1974017T5 (pl) 2023-10-23

Family

ID=37714656

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12175198T PL2540820T3 (pl) 2005-12-09 2006-12-08 Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała
PL06824300.5T PL1974017T5 (pl) 2005-12-09 2006-12-08 Środki i sposoby do wpływania na stabilność komórek wytwarzających przeciwciała

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12175198T PL2540820T3 (pl) 2005-12-09 2006-12-08 Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała

Country Status (14)

Country Link
US (3) US9127251B2 (pl)
EP (3) EP1974017B2 (pl)
JP (2) JP5753339B2 (pl)
AU (2) AU2006323315B2 (pl)
BR (2) BRPI0619579B8 (pl)
CA (2) CA3015416C (pl)
DK (2) DK2540820T3 (pl)
ES (2) ES2660899T3 (pl)
FI (1) FI1974017T4 (pl)
HU (1) HUE037580T2 (pl)
NZ (3) NZ592159A (pl)
PL (2) PL2540820T3 (pl)
PT (2) PT1974017E (pl)
WO (1) WO2007067046A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
PL2540820T3 (pl) 2005-12-09 2018-05-30 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
JP5205597B2 (ja) * 2007-06-01 2013-06-05 静岡県 １細胞レベルでの抗体遺伝子の解析・同定方法
EP2185718B1 (en) * 2007-08-03 2017-10-04 MUSC Foundation For Research Development Human monoclonal antibodies and methods for producing the same
US20110171688A1 (en) * 2008-06-16 2011-07-14 Christoph Esslinger Method of providing immunoglobulin secreting b lymphocytes and human antibodies
CN102448986B (zh) 2009-05-11 2015-11-25 克鲁塞尔荷兰公司 能中和流感病毒h3n2的人结合分子及其应用
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011062997A2 (en) 2009-11-17 2011-05-26 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
EP2400298B1 (en) * 2010-05-28 2013-08-14 F.Hoffmann-La Roche Ag Single B-cell cultivation method and specific antibody production
JP6013356B2 (ja) 2010-12-02 2016-10-25 アイム・セラピューティクス・べー・フェー 高親和性抗体を製造するための手段および方法
JP6325451B2 (ja) 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体
US10017739B2 (en) * 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
EP2971039B1 (en) 2013-03-14 2020-01-01 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
KR20240042192A (ko) 2013-12-17 2024-04-01 크링 바이오테라퓨틱스 비.브이. 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법
BR112016014881B1 (pt) 2013-12-24 2023-03-28 Kling Biotherapeutics B.V Métodos para obtenção de uma cultura de célula b ex vivo, para aumentar a vida útil replicativa de uma célula b de coelho e para obtenção de anticorpos, e, uso in vitro de pelo menos uma parte funcional do domínio extracelular de uma proteína galv e de um veículo de dispensa de genes
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
DK3152569T3 (da) * 2014-06-05 2020-08-17 Aimm Therapeutics Bv Midler og fremgangsmåder til bestemmelse af t-cellegenkendelse
JP6684211B2 (ja) 2014-07-02 2020-04-22 学校法人東京理科大学 Ｂ細胞集団の製造方法
US20180002664A1 (en) * 2014-12-19 2018-01-04 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
ES2959608T3 (es) 2015-04-03 2024-02-27 Dana Farber Cancer Inst Inc Composición y métodos de edición del genoma de células B
US11124766B2 (en) 2015-06-12 2021-09-21 Emory University Growth and survival compositions for cells capable of producing antibodies and methods related thereto
EP3313870B1 (en) 2015-06-24 2020-06-03 Aimm Therapeutics B.V. Aml antigens and uses thereof
US11136407B2 (en) 2016-01-08 2021-10-05 Aimm Therapeutics B.V. Therapeutic anti-CD9 antibody
CA3045323A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
US10908168B2 (en) 2017-01-31 2021-02-02 Vanderbilt University Generation of human allergen- and helminth-specific IgE monoclonal antibodies for diagnostic and therapeutic use
US11125757B2 (en) 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
CN111683964A (zh) * 2017-12-05 2020-09-18 Sqz生物技术公司 细胞内递送生物分子来调节抗体产生

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
EP0402402B1 (en) 1988-02-26 1995-12-27 Worcester Foundation For Biomedical Research, Inc. Inhibition of htlv-iii by exogenous oligonucleotides
US5866757A (en) * 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
WO1994007367A1 (en) * 1992-09-29 1994-04-14 Apollon, Inc. Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
KR950704482A (ko) * 1992-10-05 1995-11-20 다알렌 반스톤 치료용 항-hiv 올리고누클레오티드 및 이것을 함유하는 약제학적 제형(therapeutic anti-hiv oligonucleotide and pharmaceutical)
WO1994017086A1 (en) 1993-01-25 1994-08-04 Apollon, Inc. Gene regulation by targeting putative intramolecular triple helix
US5550019A (en) * 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
AU679120B2 (en) 1993-09-03 1997-06-19 Systemix, Inc. Genetically modified human hematopoietic stem cells and their progeny
US6265556B1 (en) * 1994-12-02 2001-07-24 The Burnham Institute Nucleic acid encoding CD40 associated proteins
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6001558A (en) * 1997-06-25 1999-12-14 Ortho Clinical Diagnostics, Inc. Amplification and detection of HIV-1 and/or HIV 2
CA2383563A1 (en) 1999-09-08 2001-03-15 Genetrol Biotherapeutics, Inc High level cytokine production with enhanced cell viability
EP1083230A1 (en) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Viral replicons and viruses dependent on inducing agents
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20050009180A1 (en) * 2001-12-10 2005-01-13 Lili Yang Method for the generation of antigen-specific lymphocytes
ATE515189T1 (de) * 2001-12-10 2011-07-15 California Inst Of Techn Verfahren zur herstellung von antigenspezifischen lymphozyten
ES2384960T3 (es) * 2001-12-18 2012-07-16 Cancer Research Technology Limited Procedimiento para la generación de líneas celulares proliferativas y que se diferencian
AU2002226390B2 (en) 2001-12-22 2007-11-15 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
AU2003224725A1 (en) 2002-03-20 2003-10-08 Brigham And Women's Hospital, Inc. Hiv therapeutic
JP2004121237A (ja) * 2002-09-05 2004-04-22 Japan Science & Technology Agency 体外免疫末梢血リンパ球を用いた抗原特異的抗体
WO2004040969A1 (ja) * 2002-11-07 2004-05-21 Kumamoto Technology & Industry Foundation Ｇａｎｐ導入トランスジェニック哺乳動物及びその利用
GB2398783A (en) * 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
RU2005131852A (ru) * 2003-03-14 2006-04-20 Уайт (Us) Антитела против человеческого рецептора il-21 и их применение
EP1694360B1 (en) 2003-11-04 2010-08-04 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
ATE474915T1 (de) * 2003-11-19 2010-08-15 Us Gov Health & Human Serv Verfahren zur induktion der entwicklung und terminalen differenzierung von gedächtnis-b- zellen
GB0327384D0 (en) 2003-11-25 2003-12-31 Queen Mary & Westfield College Gene therapy
US20050238626A1 (en) * 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
WO2005123923A2 (en) 2004-06-17 2005-12-29 Wolfgang Hillen Inducer specific tetracycline repressor proteins and methods of use thereof
EP1627563A1 (en) * 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
EP1647595A1 (en) * 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nucleic acids against viruses, in particular HIV
US7393923B2 (en) * 2004-11-08 2008-07-01 The Regents Of The University Of California Red-shifted fluorescent proteins mPlum and mRaspberry and polynucleotides encoding the same
AU2006247067B2 (en) 2005-05-18 2012-06-07 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
US20090217403A1 (en) * 2005-06-06 2009-08-27 Hergen Spits Means and methods for generating a t cell against an antigen of interest
ATE512228T1 (de) 2005-11-17 2011-06-15 Tet Systems Gmbh & Co Kg Induzierbare expressionssysteme
PL2540820T3 (pl) 2005-12-09 2018-05-30 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała
US9005974B2 (en) * 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
US8603950B2 (en) * 2007-02-20 2013-12-10 Anaptysbio, Inc. Methods of generating libraries and uses thereof
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2010113039A1 (en) * 2009-04-03 2010-10-07 Medical Research Council Mutants of activation-induced cytidine deaminase (aid) and methods of use
DK2454283T3 (en) * 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
BR112012000953A8 (pt) 2009-07-15 2017-12-26 Aimm Therapeutics Bv anticorpos de ligação a bactérias gram-positivas, sequência de ácido nucleico,seus usos e seu método de produção, células isolada ou produtora de anticorpo isolado ou recombinante, composições, e método de isolamento de bactérias
WO2011043643A1 (en) 2009-10-06 2011-04-14 Medimmune Ltd Rsv-specific binding molecule
US8568726B2 (en) * 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP6013356B2 (ja) 2010-12-02 2016-10-25 アイム・セラピューティクス・べー・フェー 高親和性抗体を製造するための手段および方法
JP6325451B2 (ja) 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体

Also Published As

Publication number Publication date
AU2014202709B2 (en) 2016-09-08
FI1974017T4 (fi) 2023-09-14
BRPI0619579A2 (pt) 2011-10-04
US20160060598A1 (en) 2016-03-03
BR122021001906B1 (pt) 2022-03-29
US9127251B2 (en) 2015-09-08
AU2014202709A1 (en) 2014-06-12
AU2006323315B2 (en) 2014-02-20
PT2540820T (pt) 2018-03-02
EP1974017A1 (en) 2008-10-01
PL2540820T3 (pl) 2018-05-30
EP1974017B1 (en) 2013-11-06
DK2540820T3 (en) 2018-03-12
HUE037580T2 (hu) 2018-09-28
DK1974017T3 (da) 2014-02-10
ES2660899T3 (es) 2018-03-26
CA2633157C (en) 2018-10-09
JP5753339B2 (ja) 2015-07-22
CA3015416C (en) 2022-10-11
BRPI0619579B1 (pt) 2021-07-20
JP2013099358A (ja) 2013-05-23
US10273454B2 (en) 2019-04-30
WO2007067046A1 (en) 2007-06-14
EP2540820A1 (en) 2013-01-02
BRPI0619579B8 (pt) 2022-01-25
JP5753547B2 (ja) 2015-07-22
EP3327117A1 (en) 2018-05-30
NZ569543A (en) 2012-12-21
PT1974017E (pt) 2014-02-11
EP1974017B2 (en) 2023-06-21
ES2444465T3 (es) 2014-02-25
AU2006323315A1 (en) 2007-06-14
CA2633157A1 (en) 2007-06-14
NZ600075A (en) 2013-12-20
US20170306293A1 (en) 2017-10-26
EP2540820B1 (en) 2018-01-10
JP2009518033A (ja) 2009-05-07
US9822339B2 (en) 2017-11-21
NZ592159A (en) 2012-12-21
ES2444465T5 (es) 2023-11-30
CA3015416A1 (en) 2007-06-14
PL1974017T5 (pl) 2023-10-23
DK1974017T4 (da) 2023-09-25
US20100113745A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
PL1974017T5 (pl) Środki i sposoby do wpływania na stabilność komórek wytwarzających przeciwciała
IL190472A (en) Glyphican Antibody 3 Methods for their preparation and use
HK1211985A1 (en) Methods for the production of ansamitocins
HK1133441A1 (en) Anti-mn antibodies and methods of using same
GB0412973D0 (en) Identification of antibody producing cells
IL191820A0 (en) Anti-ox40l antibodies and methods using same
PT2343320T (pt) Anticorpos anti-gitr e as suas utilizações
EP1915177A4 (en) ALPHA-SYNUCLEIN ANTIBODIES AND RELATED TECHNIQUES
EP1885402A4 (en) ANTIBODIES AGAINST METAPNEUMOVIRUS FROM MAMMALS
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
EP1937821A4 (en) PROCESS AND ORGANISMS FOR GROWTH-COUPLED PRODUCTION OF SUCCINATE
ZA200705425B (en) Method for the manufacture of hydrocarbons
GB0508101D0 (en) Methods and apparatus for the manufacture of microstructures
IL182940A0 (en) Solid electrolyte and method of producing the same
EP1743025A4 (en) METHOD OF MANUFACTURING REGULATOR T CELLS AND THEIR USE
EP1840084A4 (en) PROCESS FOR PRODUCING POROUS SILICA PARTICLES AND POROUS SILICA PARTICLES PRODUCED USING THE METHOD
EP1869192A4 (en) FRAME MIXTURE OF ANTIBODIES
IL177405A0 (en) Micro fuel cells and methods for the production thereof
EP2185718A4 (en) HUMAN MONOCLONAL ANTIBODIES AND METHOD FOR THEIR MANUFACTURE
GB0525567D0 (en) Novel materials and methods for the production thereof
GB0428136D0 (en) Novel materials and methods for the production thereof
ZA200704058B (en) Methods for producing mammalian cells
GB0428134D0 (en) Novel materials and methods for the production thereof
PL369540A1 (pl) Sposób wytwarzania symetrycznych mezo-tetraaryloporfiryn
PL376036A1 (pl) Sposób otrzymywania paliwa brykietowanego